Search Result for "breast cancer"
Clinical Trial
We will assess physical functioning, daily physical activity with wearable activity monitors, biological markers (serum and salivary cortisol), diet, program adherence, as well as psycho-social measures of physical, mental, and spiritual wellbeing. In addition, BCS will be asked to describe their best day possible and their typical day. We will conduct a qualitative analysis from their responses to identify endorsement of themes.
Story
Marcela Mazo Canola, MD, breast medical oncologist at Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, discusses how breast cancer has impacted the Hispanic/Latino population and the importance of breast cancer screenings. She also shares the signs of symptoms, along with the risk factors and what women can do to […]
Story
Marcela Mazo Canola, MD, helps us understand breast cancer signs, symptoms and risks.
Clinical Trial
This is an international, multicenter, open-label, randomized, Phase 3 study in patients with locally advanced, inoperable, or metastatic triple-negative breast cancer (mTNBC) who have not received previous therapy for advanced disease and whose tumors are PD-L1 positive (defined using the PD-L1 IHC 22C3 assay as tumors with a combined positive score [CPS] ≥ 10) at screening.
Story
Registration is open for the 46th annual San Antonio Breast Cancer Symposium, Dec. 5–9, at the Henry B. Gonzalez Convention Center. Experts will lead symposium discussions on clinical, translational and basic research. Attendees will receive information on experimental biology, etiology, prevention, diagnosis and therapy of breast cancer and premalignant breast disease. Click here to register.
Story
Researchers from the Mays Cancer Center at UT Health San Antonio presented results of multiple lines of study during the San Antonio Breast Cancer Symposium, operated in conjunction with the American Association of Cancer Research.
Clinical Trial
postMONARCH is a Phase 3, global, multicenter, randomized, double-blind, placebo-controlledstudy in participants with HR+, HER2- advanced or metastatic breast cancer. This study willenroll adults who experienced disease progression on a CDK4 & 6 inhibitor and an AI in thefirst-line setting or relapse on/after a CDK4 & 6 inhibitor with ET in the adjuvant setting.
Story
Lindsay Fry is a breast cancer survivor who was first diagnosed in 2019. Her treatment regimen of surgery, radiation and chemotherapy began in fall 2019. Shortly after completing her treatment, Fry became the first participant in a new clinical trial at The University of Texas Health Science Center at San Antonio (UT Health San Antonio) that aims to help breast cancer survivors regain their energy and remain cancer free.
Clinical Trial
This is an international, multicenter, open-label, randomized, Phase 3 study in patients withlocally advanced, inoperable or metastatic triple-negative breast cancer (TNBC) who have not received previous therapy for advanced disease and whose tumors are either: PD-L1 negative at screening (defined using the PD-L1 IHC 22C3 assay as tumors with a combined positive score (CPS) < 10), OR PD-L1 positive at screening (defined using the PD-L1 IHC 22C3 assay as tumors with a CPS ≥ 10) if they previously received a checkpoint inhibitor in the adjuvant or neoadjuvant setting.
Clinical Trial
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate, goserelin acetate, leuprolide acetate, anastrozole, letrozole, or exemestane, may fight breast cancer by lowering the amount of estrogen the body makes. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet know whether hormone therapy is more effective when given with or without everolimus in treating breast cancer. PURPOSE: This randomized phase III trial studies how well giving hormone therapy together with or without everolimus work in treating patients with breast cancer.